CD10 IHC (CALLA, neprilysin)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CD10-IHC |
|---|---|
| Type | Biomarker |
| Aliases | CALLA (Common Acute Lymphoblastic Leukemia Antigen)CD10 immunohistochemistryMME protein expressionNeprilysin IHC |
| Status | reviewed 2026-05-05 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-B-CELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Mutation details | {"gene_id_ncbi": 4311, "gene_symbol": "MME", "note": "CD10 (cluster of differentiation 10) is a cell-surface metalloprotease expressed on germinal center B-cells, follicular lymphoma cells, ALL blasts, endometrial stromal cells, and renal proximal tubular cells. In lymphoma context: CD10 positivity (≥30% of tumor cells) = GC origin (Hans algorithm Step 1). Membranous staining pattern.\n"} |
| Measurement | MethodIHC on FFPE biopsy. Anti-CD10 antibody (clone 56C6 or SP67). Membranous ± cytoplasmic staining. Hans algorithm cut-off: ≥30% positive tumor cells = CD10 positive (GCB assignment in DLBCL). Some algorithms use ≥20%. Automated scoring on digital platforms. |
| Related biomarkers | BIO-BCL6-IHC BIO-MUM1-IHC BIO-DLBCL-COO-HANS |
Notes
CD10 is a multi-purpose diagnostic marker in hematopathology. In DLBCL, it is the first and most specific step of the Hans algorithm — CD10+ alone classifies as GCB without needing BCL6 or MUM1. In FL, CD10 is used in the diagnostic panel (CD10+ CD20+ BCL2+ BCL6+ with follicular architecture). In B-ALL, CD10 expression is standard immunophenotyping.
Used By
Biomarker
BIO-BCL6-IHC- BCL6 IHC (protein expression)BIO-MUM1-IHC- MUM1/IRF4 IHC (Multiple Myeloma oncogene 1)